Haemonetics (NYSE:HAE) Stock Gets Downgrade from Wall Street Zen

Posted by Stanley Muller on Nov 9th, 2026

Haemonetics (NYSE:HAE – Get Free Report) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday, Wall Street Zen reports.

HAE has been the topic of several other research reports. Raymond James Financial boosted their price target on shares of Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, September 3rd. BTIG Research increased their price objective on shares of Haemonetics from $130.00 to $142.00 and gave the company a “buy” rating in a report on Thursday. Citigroup raised their price objective on Haemonetics from $123.00 to $149.00 and gave the company a “buy” rating in a research report on Friday. Barrington Research lifted their target price on Haemonetics from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Weiss Ratings upgraded Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $126.38.

Get Our Latest Report on HAE

Haemonetics Trading Down 0.1%

Shares of HAE opened at $119.87 on Friday. The firm has a market cap of $5.46 billion, a P/E ratio of 53.75, a price-to-earnings-growth ratio of 2.39 and a beta of 0.62. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.84 and a quick ratio of 1.83. Haemonetics has a 1 year low of $51.00 and a 1 year high of $132.00. The company has a 50 day simple moving average of $111.48 and a two-hundred day simple moving average of $80.05.

Haemonetics (NYSE:HAE – Get Free Report) last released its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 EPS for the quarter, topping the consensus estimate of $1.29 by $0.06. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The firm had revenue of $357.76 million for the quarter, compared to the consensus estimate of $345.15 million. During the same quarter in the previous year, the firm earned $1.27 earnings per share. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. On average, equities analysts expect that Haemonetics will post 5.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Several large investors have recently bought and sold shares of the business. Brighton Jones LLC purchased a new position in shares of Haemonetics in the 3rd quarter worth approximately $264,000. May Hill Capital LLC increased its position in shares of Haemonetics by 12.1% during the 3rd quarter. May Hill Capital LLC now owns 25,093 shares of the medical instruments supplier’s stock valued at $2,642,000 after purchasing an additional 2,705 shares during the last quarter. Vise Technologies Inc. bought a new position in shares of Haemonetics during the 3rd quarter valued at approximately $613,000. VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in Haemonetics by 178.6% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 11,700 shares of the medical instruments supplier’s stock valued at $1,232,000 after buying an additional 7,500 shares during the period. Finally, VestGen Advisors LLC purchased a new stake in Haemonetics during the 3rd quarter valued at $2,901,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics News Roundup

Here are the key news stories impacting Haemonetics this week:

Positive Sentiment: Quarterly results beat expectations: Haemonetics earned $1.35 per share versus estimates of $1.29 and generated $357.8 million in revenue, above the $345.2 million consensus and up 9.4% year over year. Earnings and outlook report
Positive Sentiment: Raised fiscal 2027 outlook: The company increased its full-year revenue and organic-growth outlook, forecasting organic growth of 6%–9%. Fiscal 2027 outlook
Positive Sentiment: Analyst price targets rose: Citigroup raised its target to $149 and maintained a Buy rating; Barrington Research lifted its target to $145 with an Outperform rating; and BTIG raised its target to $142 with a Buy rating. Citigroup recommendations
Neutral Sentiment: Growth comes with execution considerations: Haemonetics plans to scale the CSL Persona PLUS rollout through calendar 2027, and earnings-call coverage noted growth and margin tradeoffs. This may temper enthusiasm if rollout costs or margins disappoint. Earnings call highlights

Haemonetics Company Profile

(Get Free Report)

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals.

The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.

Founded in 1971, Haemonetics serves customers in multiple regions around the world.